Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11339MR)

This product GTTS-WQ11339MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11339MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13444MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ2685MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ15708MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ10432MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2495655
GTTS-WQ13078MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ4541MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ1605MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACE-536
GTTS-WQ4622MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW